HGWM
HZNP

Harvest Group Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Harvest Group Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$3.27K Hold
30
– – ﹤0.01% 102
2022
Q4 		$3.41K Sell
30
-7
-19% -$581 ﹤0.01% 96
2022
Q3 		$2K Sell
37
-33
-47% -$2.31K ﹤0.01% 126
2022
Q2 		$6K Buy
70
+14
+25% +$1.33K ﹤0.01% 98
2022
Q1 		$6K Buy
56
+1
+2% +$97 ﹤0.01% 78
2021
Q4 		$6K Buy
+55
New +$6K ﹤0.01% 62

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Harvest Group Wealth Management's HZNP Position: Q1 2023 in Review

Harvest Group Wealth Management held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q1 2023 at 30 shares worth $3.27K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

Harvest Group Wealth Management first reported a position in HZNP in Q4 2021 and has held it in 6 quarters since. The position peaked at $6K in Q2 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Harvest Group Wealth Management held 30 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.27K as of Q1 2023.
  • Harvest Group Wealth Management left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q1 2023.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Harvest Group Wealth Management's portfolio in Q1 2023, its #102 holding.
  • Harvest Group Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 6 quarters since.
  • Harvest Group Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6K in Q2 2022.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Harvest Group Wealth Management's 13F filing for Q1 2023, filed 28 Apr 2023.